Dublin, Dec. 01, 2023 (GLOBE NEWSWIRE) -- The "DUPIXENT Drug Insight and Market Forecast - 2032" report has been added to ResearchAndMarkets.com's offering.
DUPIXENT's potential as a game-changer extends further with its invention through Regeneron's proprietary VelocImmune technology. This cutting-edge technology has been instrumental in producing fully human monoclonal antibodies, propelling DUPIXENT to the forefront of medical innovation.
Dupilumab is a human monoclonal IgG4 antibody that inhibits IL-4 and IL-13 signaling. By binding specifically to the IL-4R subunit shared by the IL-4 and IL-13 receptor complexes, it effectively hampers IL-4 and IL-13 signaling through the type II receptor. In clinical trials, DUPIXENT has demonstrated its prowess in combating type 2 inflammation, a driving force behind conditions like atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyposis (CRSwNP), and EoE.
The report also highlights DUPIXENT's groundbreaking achievement as the first and only biologic to yield positive and clinically-meaningful Phase III results in patients aged 12 and older suffering from EoE. Furthermore, DUPIXENT's potential in pediatric EoE treatment is being explored through the EoE KIDS Phase III study. The FDA has also granted DUPIXENT Breakthrough Therapy Designation (BTD), Orphan Drug Designation (ODD), and Priority Review (PR), underlining its importance in the field of EoE therapy.
The Future of EoE Treatment Unveiled
The "DUPIXENT Drug Insight and Market Forecast - 2032" report promises to be a game-changer in the realm of EoE treatment. Its in-depth analysis, clinical assessment, and market evaluation will provide invaluable insights for healthcare professionals, researchers, and stakeholders in the medical fi
What to Expect from the Report
- Detailed product overview, encompassing DUPIXENT's description, mechanism of action, dosage, and administration.
- Elaborate insights into DUPIXENT's regulatory milestones and other developmental activities in EoE.
- Extensive coverage of DUPIXENT's research and development initiatives in EoE across the United States, Europe, and Japan.
- Information on patents related to DUPIXENT, including their expiry timelines.
- Sales forecasts for DUPIXENT in EoE until 2032.
- An exhaustive exploration of late-stage emerging therapies for EoE.
- SWOT analysis of DUPIXENT in EoE, with analyst perspectives.
Key Topics Covered:
1. Report Introduction
2. DUPIXENT Overview in EoE
2.1. Product Detail
2.2. Clinical Development
2.2.1. Clinical studies
2.2.2. Clinical trials information
2.2.3. Safety and efficacy
2.3. Regulatory Milestone
2.4. Other Developmental Activities
2.5. Product Profile
3. Competitive Landscape (Marketed Therapies)
4. Competitive Landscape (Late-stage Emerging Therapies)
5. DUPIXENT Market Assessment
5.1. Market Outlook of DUPIXENT in EoE
5.2. 7MM Analysis
5.2.1. Market Size of DUPIXENT in the 7MM for EoE
5.3. Country-wise Market Analysis
5.3.1. Market Size of DUPIXENT in the United States for EoE
5.3.2. Market Size of DUPIXENT in Germany for EoE
5.3.3. Market Size of DUPIXENT in France for EoE
5.3.4. Market Size of DUPIXENT in Italy for EoE
5.3.5. Market Size of DUPIXENT in Spain for EoE
5.3.6. Market Size of DUPIXENT in the United Kingdom for EoE
5.3.7. Market Size of DUPIXENT in Japan for EoE
6. SWOT Analysis
7. Analysts' Views
8. Appendix
For more information about this report visit https://www.researchandmarkets.com/r/388kil
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
